Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00390299 · ClinicalTrials.gov registry record · Phase 1
Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00390299: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT00390299 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00390299, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of carcinoembryonic antigen-expressing measles virus (MV-CEA) in treating patients with glioblastoma multiforme that has come back. A virus, called MV-CEA, which has been changed in a certain way, may be able to kill tumor cells without damaging normal cells.
Interventions
- OTHER Laboratory Biomarker Analysis
- PROCEDURE Therapeutic Conventional Surgery
- BIOLOGICAL Carcinoembryonic Antigen-Expressing Measles Virus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2006-10-23 |
| Est. Completion | 2019-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00390299
The ClinicalTrials.gov registry entry for NCT00390299 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00390299 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00390299 about?
NCT00390299 is a clinical study titled "Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme". This phase I trial studies the side effects and best dose of carcinoembryonic antigen-expressing measles virus (MV-CEA) in treating patients with glioblastoma multiforme that has come back. A virus, called MV-CEA, which has been changed in a certain way, may be able to kill tumor cells without damag...
What is the current status of trial NCT00390299?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2006-10-23. Estimated completion is 2019-11-30.
What interventions are being tested in trial NCT00390299?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Therapeutic Conventional Surgery (PROCEDURE), Carcinoembryonic Antigen-Expressing Measles Virus (BIOLOGICAL).
Who is sponsoring clinical trial NCT00390299?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.